April 25, 2008 (Chicago) — Results from the 3-year extension of an earlier randomized trial of FTY720, or fingolimod (Novartis), a still-investigational oral treatment in patients with ...

Study investigators identified patients with MS who had initiated fingolimod therapy and were followed for 3 years post first therapy administration. Although other clinical trials have found reduced ...

Study Design The preliminary efficacy and safety of fingolimod was evaluated in a Phase II, 6-month, proof-of-concept study that randomized 281 patients to receive fingolimod 1.25 mg or 5.0 mg versus ...

Oral fingolimod, a sphingosine-1-phosphate (S1P) receptor modulator, is an effective treatment for relapsing–remitting multiple sclerosis (MS), according to two double-blind, randomized controlled ...

Fingolimod therapy can cause persistent heart rate slowing in patients with preexisting parasympathetic predominance due to autonomic dysfunction. A study of 34 RRMS patients found prolonged ...

A new study indicates that rituximab is more effective than fingolimod for preventing relapses in patients with highly active multiple sclerosis switching from treatment with natalizumab. The study ...

The Appraisal Committee reviewed the data available on the clinical and cost effectiveness of fingolimod, having considered evidence on the nature of highly active relapsing–remitting multiple ...

Rituximab is more effective and better tolerated than fingolimod for patients with multiple sclerosis (MS) needing to switch from natalizumab due to JC-virus (JCV) antibody positivity, research ...

Relapsing-remitting multiple sclerosis (MS) is commonly treated with parenteral drugs that can lead to adverse events and poor adherence. Three phase 3 randomized trials evaluated the efficacy and ...

Review the side-effects of Fingolimod as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the ...

Evidence-based recommendations on fingolimod (Gilenya) for highly active relapsing-remitting multiple sclerosis. July 2019: Fingolimod is contraindicated during pregnancy and in women of childbearing ...